DxCodebookFY2027 · Oct 1, 2026 – Sep 30, 2027

Category · FY2027

R97 Abnormal tumor markers

  • Header · not billable

R97 is not billable. The category heads 5 billable codes in FY2027, grouped under 4 subdivisions.

Index → code

  • Rising, PSA following treatment for malignant neoplasm of prostate → R97.21
  • Elevated, elevationcancer antigen 125 [CA 125] → R97.1
  • Elevated, elevationcarcinoembryonic antigen [CEA] → R97.0

Where it sits

  1. Chapter 18 Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R99)
  2. R97 Abnormal tumor markers (R97)
  3. R97 Abnormal tumor markers
Billable codes
5
Subdivisions
4
CC / MCC codes
0 / 0
HCC V28 codes
0
New FY2027
0
Index entries
7

Codes in R97

  1. R97.0
    Elevated carcinoembryonic antigen [CEA]
    Billable
  2. R97.1
    Elevated cancer antigen 125 [CA 125]
    Billable
  3. R97.2
    Elevated prostate specific antigen [PSA]
    Header
  4. R97.20
    Elevated prostate specific antigen [PSA]
    Billable
  5. R97.21
    Rising PSA following treatment for malignant neoplasm of prostate
    Billable
  6. R97.8
    Other abnormal tumor markers
    Billable

Sources of each column.

Instructions

At R97

Inclusion terms

  • Elevated tumor associated antigens [TAA]
  • Elevated tumor specific antigens [TSA]

Notes that also apply

Chapter 18 instructions (Notes 9, Excludes2 4): printed on the chapter 18 page.

Index entries

  • Rising, PSA following treatment for malignant neoplasm of prostate → R97.21
  • Elevated, elevationcarcinoembryonic antigen [CEA] → R97.0
  • Elevated, elevationcancer antigen 125 [CA 125] → R97.1
  • Elevated, elevationprostate specific antigen [PSA] → R97.20
  • Abnormal, abnormality, abnormalitiestumor marker NEC → R97.8
  • Elevated, elevationtumor associated antigens [TAA] NEC → R97.8
  • Elevated, elevationtumor specific antigens [TSA] NEC → R97.8

NCHS Alphabetic Index. Index first, then the Tabular List.